Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. Company news centers on financial and operational results, gross margin and cash flow trends, supply-chain and distribution initiatives, and customer activity tied to dialysis clinics and large dialysis-service providers.
Recurring updates also cover product purchase agreements, expanded delivery capabilities in U.S. regions, additions to the customer clinic footprint, operational changes aimed at improving gross profit, and corporate communications such as earnings release schedules and workplace-related announcements.
Rockwell Medical has appointed Dr. Allen R. Nissenson to its Board of Directors effective June 11, 2020. An expert in kidney disease and former Chief Medical Officer of DaVita Kidney Care, Dr. Nissenson's extensive experience is expected to bolster the company's mission of enhancing anemia management in end-stage renal disease (ESRD) patients. This strategic move aims to strengthen Rockwell's leadership as it seeks to expand the reach of its FDA-approved products, Triferic Dialysate and Triferic AVNU, both crucial for iron replacement in hemodialysis patients.
Rockwell Medical (Nasdaq: RMTI) announced the submission of a New Drug Submission (NDS) to Health Canada for Triferic AVNU, an iron replacement therapy for adult hemodialysis patients with chronic kidney disease. This marks the Company's first international regulatory filing for this intravenous drug. If approved, Triferic AVNU is expected to become a vital treatment option in Canada, benefiting over 20,000 patients. Rockwell Medical has a distribution agreement with RMC Canada, contingent on regulatory approval.